Delcath Systems Raises 2026 Product Revenue Outlook to $115 Million-$117 Million

Delcath Systems Inc. raised its 2026 revenue forecast for HEPZATO KIT and CHEMOSAT to $115 million to $117 million after quarterly sales of both offerings climbed from a year earlier.

The full-year outlook reflects expected HEPZATO KIT volume growth of at least 41% over 2025. Delcath also projects gross margins of 87% to 89% and positive adjusted earnings before interest, taxes, depreciation and amortization.

Third-quarter revenue reached $35.1 million, up from $20.6 million in the same period of 2025. HEPZATO KIT brought in $32.7 million, compared with $19.3 million a year earlier. CHEMOSAT revenue rose to $2.4 million from $1.3 million.

Delcath reported 33 active treatment centers. HEPZATO treatment volume grew approximately 72% from the third quarter of 2025. The company develops treatments for cancers affecting the liver, with HEPZATO KIT sales in the United States and CHEMOSAT sales in Europe.

Third-quarter net income was $7 million, compared with $0.8 million a year earlier. Delcath held $104.3 million in cash and investments as of Sept. 30 and reported no debt.

Delcath plans to submit an investigational new drug application for cholangiocarcinoma in early 2027.